| 產(chǎn)品名稱 | L2-RYC |
|---|---|
| 商品貨號 | B164943 |
| Organism | Rattus norvegicus, rat |
| Tissue | embryo |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | Carcinoma |
| Age | embryo; 10 days gestation |
| Strain | Lewis |
| Applications | The cell line expresses parietal yolk sac endoderm characteristics in that it synthesizes basement membrane components. Alpha fetoprotein synthesis could not be demonstrated. |
| Storage Conditions | liquid nitrogen vapor phase |
| Karyotype | The majority of cells had a pseudodiploid chromosome complement; approximately 10% of cells were pseudotetraploid. |
| Derivation | L2-RYC is a yolk sac carcinoma established in 1978 by Dr. Ulla Wewer from a yolk sac tumor induced by puncturing a Lewis rat embryo through the wall of the uterus at the 10th day of gestation. A yolk sac carcinoma developed approximately 71/2 months later. The L2 cell line in which only parietal carcinoma cells could be identified, was established from transplant number 14. In the early passages of the parental cell line, designated L1, both visceral and parietal yolk sac carcinomas were present. |
| Genes Expressed | laminin; entactin; collagen IV; heparin sulfate proteoglycan; chondroitin sulfate proteoglycan |
| Cellular Products | laminin; entactin; collagen IV; heparin sulfate proteoglycan; chondroitin sulfate proteoglycan |
| Tumorigenic | Yes |
| Effects | Yes, in Lewis rats |
| Comments | L2-RYC is a yolk sac carcinoma established in 1978 by Dr. Ulla Wewer from a yolk sac tumor induced by puncturing a Lewis rat embryo through the wall of the uterus at the 10th day of gestation.
A yolk sac carcinoma developed approximately 71/2 months later.
In the early passages of the parental cell line, designated L1, both visceral and parietal yolk sac carcinomas were present.
L1 cells were injected intraperitoneally into rats and serial transplantations were carried out.
The L2 cell line in which only parietal carcinoma cells could be identified, was established from transplant number 14.
The cell line expresses parietal yolk sac endoderm characteristics in that it synthesizes basement membrane components.
In addition, a noncartilage chondroitin sulfate proteoglycan is synthesized.
Alpha fetoprotein synthesis could not be demonstrated.
The cells must be subcultured frequently and not be allowed to become dense. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing | Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation Ratio: 1:5 Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a Manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994. |
| Cryopreservation | Complete growth medium described above supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Name of Depositor | S Thorgeirsson |
| Deposited As | Rattus sp. |
| Year of Origin | 1978 |
| References | Wewer UM, et al. Heparan sulfate proteoglycans made by different basement-membrane- producing tumors have immunological and structural similarities. Differentiation 30: 61-67, 1985. PubMed: 2936642 Wewer U. Characterization of a rat yolk sac carcinoma cell line. Dev. Biol. 93: 416-421, 1982. PubMed: 7141105 Wewer U, et al. Laminin, a noncollagenous component of epithelial basement membranes synthesized by a rat yolk sac tumor. Cancer Res. 41: 1518-1524, 1981. PubMed: 7011537 . . Acta Pathol. Scand. Immunol. Sect. A, Immunol. 92: 275-283, 1984. Oldberg A, et al. Isolation of a chondroitin sulfate proteoglycan from a rat yolk sac tumor and immunochemical demonstration of its cell surface localization. J. Biol. Chem. 256: 10847-10852, 1981. PubMed: 6793588 Lundstrom M, et al. Immunocytochemical and biochemical characterization of the Heymann nephritis antigenic complex in rat L2 yolk sac cells. Am. J. Pathol. 143: 1423-1435, 1993. PubMed: 8238258 Orlando RA, Farquhar MG. Identification of a cell line that expresses a cell surface and a soluble form of the gp330/receptor-associated protein (RAP) Heymann nephritis antigenic complex. Proc. Natl. Acad. Sci. USA 90: 4082-4086, 1993. PubMed: 8483924 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
